GlassScriptPhysician profile
Matthew L Oswalt
NPI 1679784599
$13,066.85
in general payments reported to CMS, 2019-2025
30 companies · $2,474 in 2025
The $2,474 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,692 · 2020: $1,234 · 2021: $1,515 · 2022: $1,822 · 2023: $2,408 · 2024: $1,923 · 2025: $2,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,594 · Education: $194 · Consulting Fee: $16.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,593.51 |
| Education | $193.65 |
| Consulting Fee | $16.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $1,927.42 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Astrazeneca Pharmaceuticals LP | $1,774.10 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $1,416.59 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,349.91 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genentech USA, INC. | $1,314.59 | 2019-2025 | Xolair |
| Amgen INC. | $1,044.41 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $777.68 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $762.84 | 2019-2025 | Dupixent |
| Pfizer INC. | $406.74 | 2019-2025 | |
| Grifols USA, LLC | $282.27 | 2020-2024 | Xembify, Prolastin-C Liquid |
| Biocryst US Sales Co., LLC | $242.88 | 2021-2025 | Orladeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.71 | 2020-2023 | Spiriva Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $220.80 | 2020-2025 | Eohilia, Cuvitru |
| Pharming Healthcare, INC. | $216.86 | 2019-2025 | Ruconest |
| Leo Pharma INC. | $196.04 | 2022-2025 | Adbry |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $172.40 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $142.14 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $98.99 | 2025 | |
| Lilly USA, LLC | $71.21 | 2024-2025 | Ebglyss |
| Ars Pharmaceuticals Operations, INC. | $51.47 | 2025 | Neffy |
| Organon LLC | $48.51 | 2025 | Vtama |
| Boston Scientific Corporation | $48.44 | 2024 | |
| Ionis Pharmaceuticals, INC. | $46.36 | 2025 | Dawnzera |
| Galderma Laboratories, L.P. | $42.58 | 2025 | Nemluvio |
| Uswm, LLC | $38.40 | 2021 | |
| Kaleo, INC. | $38.28 | 2022-2023 | Auvi-Q |
| Biocryst Pharmaceuticals, INC. | $37.68 | 2020 | |
| Blueprint Medicines Corporation | $24.62 | 2024 | Ayvakit |
| Shire North American Group INC | $18.95 | 2019 | |
| Adma Biomanufacturing LLC | $16.98 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Oswalt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.